Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE
Aims In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs in AHF is yet to be explored. This study aimed...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 2023
|
| In: |
European journal of heart failure
Year: 2023, Volume: 25, Issue: 10, Pages: 1797-1805 |
| ISSN: | 1879-0844 |
| DOI: | 10.1002/ejhf.2982 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ejhf.2982 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2982 
|
| Author Notes: | João Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin-Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, and Adriaan A. Voors |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1897877315 | ||
| 003 | DE-627 | ||
| 005 | 20241205160440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240806s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.2982 |2 doi | |
| 035 | |a (DE-627)1897877315 | ||
| 035 | |a (DE-599)KXP1897877315 | ||
| 035 | |a (OCoLC)1475305910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pedro Ferreira, João |e VerfasserIn |0 (DE-588)1239313632 |0 (DE-627)1767400063 |4 aut | |
| 245 | 1 | 0 | |a Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure |b findings from EMPULSE |c João Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin-Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, and Adriaan A. Voors |
| 264 | 1 | |c October 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 4. August 2023 | ||
| 500 | |a Gesehen am 06.08.2024 | ||
| 520 | |a Aims In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs in AHF is yet to be explored. This study aimed to evaluate the efficacy and safety of empagliflozin versus placebo according to MRA use at baseline in the EMPULSE trial (NCT04157751). Methods and results In this analysis all comparisons were performed between empagliflozin and placebo, stratified by baseline MRA use. The primary outcome included all-cause death, heart failure events, and a ≥5 point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score at 90 days, assessed using the win ratio (WR). First heart failure hospitalization or cardiovascular death was a secondary outcome. From the 530 patients randomized, 276 (52%) were receiving MRAs at baseline. MRA users were younger, had lower ejection fraction, better renal function, and higher KCCQ scores. The primary outcome showed benefit of empagliflozin irrespective of baseline MRA use (WR 1.46, 95% confidence interval [CI] 1.08-1.97 and WR 1.27, 95% CI 0.93-1.73 in MRA users and non-users, respectively; interaction p = 0.52). The effect of empagliflozin on first heart failure hospitalization or cardiovascular death was not modified by MRA use (hazard ratio [HR] 0.58, 95% CI 0.30-1.11 and HR 0.85, 95% CI 0.47-1.52 in MRA users and non-users, respectively; interaction p = 0.39). Investigator-reported and severe hyperkalaemia events were infrequent (<6%) irrespective of MRA use. Conclusions In patients admitted for AHF, initiation of empagliflozin produced clinical benefit and was well tolerated irrespective of background MRA use. These findings support the early use of empagliflozin on top of MRA therapy in patients admitted for AHF. | ||
| 650 | 4 | |a Acute heart failure | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a Mineralocorticoid receptor antagonists | |
| 700 | 1 | |a Blatchford, Jonathan P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teerlink, John R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kosiborod, Mikhail N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Angermann, Christiane E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Biegus, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Collins, Sean P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tromp, Jasper |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nassif, Michael E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Psotka, Mitchell A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Comin-Colet, Josep |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mentz, Robert J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Nordaby, Matias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Voors, Adriaan A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d Oxford : Wiley, 1999 |g 25(2023), 10, Seite 1797-1805 |h Online-Ressource |w (DE-627)306658291 |w (DE-600)1500332-2 |w (DE-576)081985983 |x 1879-0844 |7 nnas |a Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure findings from EMPULSE |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g pages:1797-1805 |g extent:9 |a Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure findings from EMPULSE |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ejhf.2982 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2982 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240806 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 13 | ||
| 999 | |a KXP-PPN1897877315 |e 4563048402 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["João Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin-Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, and Adriaan A. Voors"]},"title":[{"title_sort":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure","title":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure","subtitle":"findings from EMPULSE"}],"person":[{"display":"Pedro Ferreira, João","given":"João","roleDisplay":"VerfasserIn","role":"aut","family":"Pedro Ferreira"},{"family":"Blatchford","roleDisplay":"VerfasserIn","role":"aut","display":"Blatchford, Jonathan P.","given":"Jonathan P."},{"given":"John R.","display":"Teerlink, John R.","family":"Teerlink","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Kosiborod","role":"aut","roleDisplay":"VerfasserIn","display":"Kosiborod, Mikhail N.","given":"Mikhail N."},{"given":"Christiane E.","display":"Angermann, Christiane E.","family":"Angermann","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Biegus","role":"aut","roleDisplay":"VerfasserIn","given":"Jan","display":"Biegus, Jan"},{"family":"Collins","roleDisplay":"VerfasserIn","role":"aut","given":"Sean P.","display":"Collins, Sean P."},{"display":"Tromp, Jasper","given":"Jasper","roleDisplay":"VerfasserIn","role":"aut","family":"Tromp"},{"given":"Michael E.","display":"Nassif, Michael E.","family":"Nassif","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Psotka","display":"Psotka, Mitchell A.","given":"Mitchell A."},{"given":"Josep","display":"Comin-Colet, Josep","family":"Comin-Colet","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Mentz","display":"Mentz, Robert J.","given":"Robert J."},{"family":"Brückmann","role":"aut","roleDisplay":"VerfasserIn","given":"Martina","display":"Brückmann, Martina"},{"display":"Nordaby, Matias","given":"Matias","roleDisplay":"VerfasserIn","role":"aut","family":"Nordaby"},{"display":"Ponikowski, Piotr","given":"Piotr","family":"Ponikowski","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Voors","display":"Voors, Adriaan A.","given":"Adriaan A."}],"language":["eng"],"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"recId":"1897877315","id":{"doi":["10.1002/ejhf.2982"],"eki":["1897877315"]},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"October 2023"}],"note":["Online veröffentlicht: 4. August 2023","Gesehen am 06.08.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"disp":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure findings from EMPULSEEuropean journal of heart failure","title":[{"subtitle":"journal of the Working Group on Heart Failure of the European Society of Cardiology","title":"European journal of heart failure","title_sort":"European journal of heart failure"}],"titleAlt":[{"title":"EJHF"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 12.06.15"],"origin":[{"dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Oxford ; Amsterdam [u.a.] ; Oxford [u.a.]","publisher":"Wiley ; Elsevier Science ; Oxford Univ. Press"}],"pubHistory":["1.1999 -"],"part":{"year":"2023","text":"25(2023), 10, Seite 1797-1805","pages":"1797-1805","extent":"9","issue":"10","volume":"25"},"recId":"306658291","id":{"zdb":["1500332-2"],"eki":["306658291"],"doi":["10.1002/(ISSN)1879-0844"],"issn":["1879-0844"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"]}]} | ||
| SRT | |a PEDROFERREMINERALOCO2023 | ||